EP1515748A4 - COMBINATIONS OF ANTIOESTROGENES AND IMMUNOMODULATORS TO TREAT BREAST CANCER - Google Patents

COMBINATIONS OF ANTIOESTROGENES AND IMMUNOMODULATORS TO TREAT BREAST CANCER

Info

Publication number
EP1515748A4
EP1515748A4 EP02793936A EP02793936A EP1515748A4 EP 1515748 A4 EP1515748 A4 EP 1515748A4 EP 02793936 A EP02793936 A EP 02793936A EP 02793936 A EP02793936 A EP 02793936A EP 1515748 A4 EP1515748 A4 EP 1515748A4
Authority
EP
European Patent Office
Prior art keywords
antioestrogenes
immunomodulators
combinations
breast cancer
treat breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02793936A
Other languages
German (de)
French (fr)
Other versions
EP1515748A2 (en
Inventor
David A Sirbasku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signe BioPharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1515748A2 publication Critical patent/EP1515748A2/en
Publication of EP1515748A4 publication Critical patent/EP1515748A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP02793936A 2001-11-14 2002-11-13 COMBINATIONS OF ANTIOESTROGENES AND IMMUNOMODULATORS TO TREAT BREAST CANCER Withdrawn EP1515748A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33280101P 2001-11-14 2001-11-14
US332801P 2001-11-14
PCT/US2002/036633 WO2003041654A2 (en) 2001-11-14 2002-11-13 Anti-estrogen and immune modulator combinations for treating breast cancer

Publications (2)

Publication Number Publication Date
EP1515748A2 EP1515748A2 (en) 2005-03-23
EP1515748A4 true EP1515748A4 (en) 2006-04-12

Family

ID=23299909

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02793936A Withdrawn EP1515748A4 (en) 2001-11-14 2002-11-13 COMBINATIONS OF ANTIOESTROGENES AND IMMUNOMODULATORS TO TREAT BREAST CANCER

Country Status (3)

Country Link
EP (1) EP1515748A4 (en)
AU (1) AU2002359401A1 (en)
WO (1) WO2003041654A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201490897A1 (en) * 2011-12-16 2015-03-31 Олема Фармасьютикалс, Инк. NEW BENZOPYRANE COMPOUNDS, COMPOSITIONS AND THEIR APPLICATION

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
US4919937A (en) * 1984-01-20 1990-04-24 Mauvais Jarvis Pierre Percutaneous administration of tamoxifen
EP1366366A2 (en) * 2000-05-10 2003-12-03 David A. Sirbasku Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261787B1 (en) * 1996-06-03 2001-07-17 Case Western Reserve University Bifunctional molecules for delivery of therapeutics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919937A (en) * 1984-01-20 1990-04-24 Mauvais Jarvis Pierre Percutaneous administration of tamoxifen
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
EP1366366A2 (en) * 2000-05-10 2003-12-03 David A. Sirbasku Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRODIE A ET AL: "Aromatase inhibitors and their antitumor effects in model systems.", ENDOCRINE-RELATED CANCER. JUN 1999, vol. 6, no. 2, June 1999 (1999-06-01), pages 205 - 210, XP002367011, ISSN: 1351-0088 *
MCCORMICK DAVID L ET AL: "Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland", CANCER RESEARCH, vol. 56, no. 8, 1996, pages 1724 - 1726, XP008057031, ISSN: 0008-5472 *
ROSSO R ET AL: "ADJUVANT SYSTEMIC TREATMENT OF RESECTABLE BREAST CANCER ELEVEN YEARS RESULTS OF A MONOINSTITUTIONAL CHEMO-HORMONE-IMMUNOTHERAPY TRIAL", ANTICANCER RESEARCH, vol. 9, no. 4, 1989, pages 1153 - 1156, XP008057015, ISSN: 0250-7005 *
SAVAGE P ET AL: "A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily", BRITISH JOURNAL OF CANCER, vol. 74, no. 9, 1996, pages 1482 - 1486, XP002073161, ISSN: 0007-0920 *
SAWAI K ET AL: "CHEMO-ENDOCRINE-IMMUNOTHERAPY WITH ADRIAMYCIN TAMOXIFEN AND OK-432 PICIBANIL FOR ADVANCED BREAST CANCER", JOURNAL OF JAPAN SOCIETY FOR CANCER THERAPY, vol. 19, no. 6, 1984, pages 1315 - 1320, XP008057016, ISSN: 0021-4671 *

Also Published As

Publication number Publication date
WO2003041654A2 (en) 2003-05-22
AU2002359401A1 (en) 2003-05-26
WO2003041654A3 (en) 2005-01-06
EP1515748A2 (en) 2005-03-23

Similar Documents

Publication Publication Date Title
AU6147401A (en) Compositions and methods for the treatment of cancer
EP1438062A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF SKIN LESIONS
EP1446012A4 (en) COMBINED BACTERIOLYTIC THERAPY FOR THE TREATMENT OF TUMORS
FR13C0060I2 (en) FLUORO-SUBSTITUTED OMEGA-CARBOXYARYLDIPHENYLUREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS
ATE323661T1 (en) TREATMENT OF MINERAL SUBSTANCES
NO20024610D0 (en) Synergistic methods and compositions for the treatment of cancer
PL356908A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU5160201A (en) Compositions comprising natural agents for treatment of cancer
EP1575577A4 (en) COMPOSITION FOR THE PREVENTION AND TREATMENT OF INFLAMMATION OF THE EAR
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
EP1553920A4 (en) TOPICAL PREPARATION FOR THE PREVENTION AND TREATMENT OF ACNE
EP1416960A4 (en) ANTIBODIES AGAINST VEGFR-1 TO TREAT BREAST CANCER
EP1463495A4 (en) Agents and methods for treatment of cancer
IL161059A0 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
EP1373221A4 (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
IL145397A0 (en) Compositions and methods for treatment of cancer
PL366066A1 (en) Compositions and methods of treatment and diagnosis of breast cancer
PL368035A1 (en) Compositions and methods for the treatment of cancer
NO20030978L (en) Treatment of urinary dysfunction
EP1349485A4 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
FR2828647B1 (en) MAKE-UP SKIN CARE FOR THE TREATMENT AND PREVENTION OF AGING
EP1161255A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSERECTION
EP1454626A4 (en) METHOD OF INDUCING APOPTOSIS AND COMPOSITIONS THEREOF
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SIRBASKU, DAVID A.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SIRBASKU, DAVID A.

17P Request for examination filed

Effective date: 20050615

A4 Supplementary search report drawn up and despatched

Effective date: 20060224

17Q First examination report despatched

Effective date: 20070214

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SIGNE BIOPHARMA INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SIRBASKU, DAVID A.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SIGNE BIOPHARMA INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080710